Binh Nguyen, M.D., Ph.D., serves as vice president of oncology in global product development at PPD. Dr. Nguyen provides consultation to biopharma companies on the clinical development of their assets and supports PPD’s overall oncology business, ensuring that company personnel are aware of updates in the immuno-oncology field across all functions to remain on the frontlines of innovation.
At PPD, Dr. Nguyen is a member of the oncology therapeutic area strategy team and the Immuno-oncology Center of Excellence. Working in collaboration with the clinical operations team, Dr. Nguyen provides expert medical consultation on topics such as clinical development, study design and site selection that maximize the probability of study success by ensuring efficient and timely execution. Internally, Dr. Nguyen leads training to ensure that PPD personnel are equipped to maintain pace with the evolving immuno-oncology field. Upon request, he also provides consultation to biopharma companies on topics such as clinical development and regulatory approval pathway.
Dr. Nguyen joined PPD in 2015 and continues to add to his 25 years of regulatory and clinical development experience with both large biopharma and startup biotech companies. In his previous role as executive director of a global oncology platform team and pharmacogenomics program at a large pharma company, Dr. Nguyen held extensive interactions and negotiations with regulatory agencies worldwide that led to the submission and worldwide approval of two drugs in six oncology indications. As vice president of a mid-sized biopharma company, he was responsible for the clinical development of a folate receptor and PSMA targeted anti-cancer and anti-inflammatory agents in conjunction with companion diagnostic imaging agents. As a chief medical officer in private industry, he focused on the clinical development of novel cancer agents licensed from the National Cancer Institute (NCI) and academic institutions.
Dr. Nguyen holds a Bachelor of Science in chemistry and a Ph.D. in organic chemistry, both from Georgetown University in Washington, D.C., and a medical degree from the University of Maryland. After completing his internal medicine residency at Georgetown and his medical oncology fellowship at NCI, he worked at the NCI Cancer Therapy Evaluation Program (CTEP), as well as the U.S. Food and Drug Administration’s (FDA) Division of Oncology Products prior to joining the biopharma industry.